UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
The Lancet (British edition), ISSN 0140-6736, 2010, Volume 376, Issue 9753, pp. 1658 - 1669
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Myocardial Infarction - blood | Double-Blind Method | Simvastatin - administration & dosage | Humans | Middle Aged | Male | Hypercholesterolemia - drug therapy | Anticholesteremic Agents - adverse effects | Young Adult | Myocardial Infarction - complications | Anticholesteremic Agents - administration & dosage | Triglycerides - blood | Aged, 80 and over | Cholesterol, HDL - blood | Adult | Cholesterol, LDL - blood | Female | Hypercholesterolemia - complications | Aged | Heart attacks | Hospitals | Compliance | Cardiovascular disease | Kinases | Cholesterol | Statins | Index Medicus | Abridged Index Medicus | Anticholesteremic Agents | drug therapy | complications | Simvastatin | Triglycerides | MEDICIN OCH HÄLSOVETENSKAP | blood | 80 and over | HDL | Myocardial Infarction | Hypercholesterolemia | administration & dosage | LDL | adverse effects | MEDICAL AND HEALTH SCIENCES
Journal Article
The New England journal of medicine, ISSN 0028-4793, 08/2008, Volume 359, Issue 8, pp. 789 - 799
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Biological and medical sciences | General aspects | Medical sciences | Simvastatin - therapeutic use | Simvastatin - adverse effects | Humans | Middle Aged | Diabetes Mellitus - drug therapy | Genotype | Male | Risk | Genetic Markers | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Organic Anion Transporters - genetics | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Myocardial Infarction - drug therapy | Arterial Occlusive Diseases - drug therapy | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Female | Aged | Myocardial Infarction - prevention & control | Polymorphism, Single Nucleotide | Chromosomes, Human, Pair 12 | Muscular Diseases - chemically induced | Muscular Diseases - genetics | Solute Carrier Organic Anion Transporter Family Member 1b1 | Complications and side effects | Analysis | Muscle diseases | Genetic aspects | Dosage and administration | Single nucleotide polymorphisms | Risk factors | Statins | Drug therapy | Kinases | Drug dosages | Cholesterol | Index Medicus | Abridged Index Medicus | MEDICIN OCH HÄLSOVETENSKAP | Single Nucleotide | genetics | Arterial Occlusive Diseases | pharmacokinetics | Muscular Diseases | Hydroxymethylglutaryl-CoA Reductase Inhibitors | Chromosomes | MEDICAL AND HEALTH SCIENCES | Human | drug therapy | chemically induced | Simvastatin | prevention & control | Diabetes Mellitus | Myocardial Infarction | Pair 12 | Organic Anion Transporters | adverse effects | therapeutic use | Polymorphism
Journal Article
The lancet oncology, ISSN 1470-2045, 01/2018, Volume 19, Issue 1, pp. 27 - 39
Life Sciences & Biomedicine | Oncology | Science & Technology | Humans | Middle Aged | Risk Factors | Neoplasm Recurrence, Local | Treatment Outcome | Antineoplastic Agents - administration & dosage | Breast Neoplasms - drug therapy | Disease Progression | Randomized Controlled Trials as Topic | Neoadjuvant Therapy - mortality | Neoplasm Metastasis | Time Factors | Antineoplastic Agents - adverse effects | Breast Neoplasms - pathology | Mastectomy, Segmental | Neoadjuvant Therapy - adverse effects | Adult | Breast Neoplasms - mortality | Female | Chemotherapy, Adjuvant | Neoplasm Staging | Lumpectomy | Medical research | Anthracyclines | Patient outcomes | Analysis | Mortality | Adjuvant treatment | Medicine, Experimental | Breast cancer | Rankings | Cancer | Index Medicus | Medicin och hälsovetenskap
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2005, Volume 366, Issue 9503, pp. 2087 - 2106
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Gynecology. Andrology. Obstetrics | Mammary gland diseases | Biological and medical sciences | General aspects | Medical sciences | Tumors | Breast Neoplasms - surgery | Humans | Middle Aged | Probability | Cause of Death | Randomized Controlled Trials as Topic | Disease-Free Survival | Breast Neoplasms - radiotherapy | Time Factors | Breast Neoplasms - mortality | Female | Aged | Neoplasm Recurrence, Local - epidemiology | Evaluation | Complications and side effects | Care and treatment | Patient outcomes | Breast cancer | Radiotherapy | Cancer | Relapse | Surgery | Breast | Health aspects | Risk factors | Diseases | Therapy | Side effects | Mortality | Radiology | Health risk assessment | Index Medicus | Abridged Index Medicus | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Cancer and Oncology | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2005, Volume 365, Issue 9472, pp. 1687 - 1717
UMCG Approved | TAMOXIFEN | DEATHS | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Ovariectomy | Humans | Middle Aged | Neoplasm Recurrence, Local | Survival Rate | Receptors, Estrogen - analysis | Breast Neoplasms - drug therapy | Cause of Death | Randomized Controlled Trials as Topic | Breast Neoplasms - therapy | Neoplasm Metastasis | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Antineoplastic Agents, Hormonal - therapeutic use | Tamoxifen - therapeutic use | Breast Neoplasms - mortality | Female | Ovary - drug effects | Aged | Anthracyclines - therapeutic use | Chemotherapy, Adjuvant | Chemotherapy | Breast cancer | Diagnosis | Research | Drug therapy | Health aspects | Cancer | Clinical trials | Prescription drugs | Hormone replacement therapy | Mortality | Index Medicus | Abridged Index Medicus | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Cancer and Oncology | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article